10x Genomics Navigates Revenue Dip with New Launches
Company Announcements

10x Genomics Navigates Revenue Dip with New Launches

10x Genomics ( (TXG) ) has shared an update.

10x Genomics reported a slight decrease in third-quarter revenue to $151.7 million, primarily due to lower instrument sales, but noted strong performance from consumables. Despite challenges from sales restructuring and cautious customer spending, the company launched new products like GEM-X Flex and Chromium Xo to drive cost-effective research. CEO Serge Saxonov expressed confidence in reaching more customers and achieving long-term growth despite lowering the annual revenue forecast.

For an in-depth examination of TXG stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFly10x Genomics’ Visium HD selected by TechBio startup Cure51
TipRanks Auto-Generated Newsdesk10X Genomics CEO Serge Saxonov Initiates Rule 10b5-1 Trading Plan Amid Strategic Financial Maneuvering
TheFly10x Genomics price target lowered to $23 from $35 at Citi
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App